Use of linezolid in children: an overview of recent advances (Q36688930)

15 August 2017

1 reference

title

Use of linezolid in children: an overview of recent advances (English)

1 reference

15 August 2017

1 reference

Ioanna M Velissariou

1

1 reference

15 August 2017

publication date

1 December 2006

1 reference

Expert Review of Anti-infective Therapy

15 August 2017

published in

1 reference

15 August 2017

volume

4

1 reference

15 August 2017

issue

6

1 reference

15 August 2017

page(s)

947-952

1 reference

Quinupristin/dalfopristin and linezolid: where, when, which and whether to use?

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.6.947

Oxazolidinone antibiotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.6.947

The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.6.947

Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.6.947

Linezolid in the treatment of vancomycin‐resistant Enterococcus faecium in solid organ transplant recipients: report of a multicenter compassionate‐use trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.6.947

Epidemiology and treatment of community-associated methicillin-resistant Staphylococcus aureus in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.6.947

Antibiotics for treatment of resistant gram-positive coccal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.6.947

In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.6.947

Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.6.947

Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.6.947

Activities of linezolid against rapidly growing mycobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.6.947

Clinical experience with linezolid for the treatment of nocardia infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.6.947

Children hospitalized with skin and soft tissue infections: a guide to antibacterial selection and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.6.947

Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.6.947

Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.6.947

Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.6.947

Update on the use of linezolid: a pediatric perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.6.947

Pharmacokinetics and tissue penetration of linezolid following multiple oral doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.6.947

Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.6.947

Linezolid pharmacokinetics in pediatric patients: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.6.947

Impact of ontogeny on linezolid disposition in neonates and infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.6.947

Single dose pharmacokinetics of linezolid in infants and children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.6.947

Use of linezolid in children. Introduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.6.947

Staphylococcal skin infections in children: rational drug therapy recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.6.947

Linezolid for the treatment of community-acquired pneumonia in hospitalized children. Linezolid Pediatric Pneumonia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.6.947

Linezolid for the treatment of complicated skin and skin structure infections in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.6.947

Enterococcal infection in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.6.947

Clinical Pharmacokinetics of Linezolid, a Novel Oxazolidinone Antibacterial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.6.947

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.6.947

Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.6.947

Safety and tolerability of linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.6.947

Hematologic effects of linezolid in young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.6.947

Peripheral neuropathy associated with prolonged use of linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.6.947

Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.6.947

Linezolid-induced inhibition of mitochondrial protein synthesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.6.947

Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.6.947

Successful medical treatment of multiple brain abscesses due to Nocardia farcinica in a paediatric renal transplant recipient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.6.947

21 January 2018

Identifiers

DOI

10.1586/14787210.4.6.947

1 reference

15 August 2017

1 reference